Eden Rahim, portfolio manager and options strategist at Next Edge Capital, says the buying opportunity in late-stage biotech stocks is the best he's ever seen. We talk valuations, takeover activity, drug discovery and Rahim's top picks which include Acadia Pharmaceuticals, Portola Pharma and Neurocrine Bioscience.